Mechanistic target of rapamycin complex 1 (mTORC1) via FKBP12–FRB ternary complex (mTORC1/FKBP12/FRB)

The mechanistic target of rapamycin complex 1 (mTORC1) is a central signaling hub that coordinates cellular growth and metabolism in response to environmental cues such as nutrients and growth factors (Source: UniProt P42345). A distinctive pharmacological characteristic of this target is its sensitivity to rapamycin and its analogs (rapalogs), which inhibit the complex by forming a stable ternary complex with the 12 kDa FK506-binding protein (FKBP12) and the FKBP12-rapamycin binding (FRB) domain of mTOR (Source: PubMed PMC2172251). This interaction acts as a molecular glue, where the FKBP12-drug complex sterically hinders the access of substrates to the mTOR catalytic site or induces allosteric changes that reduce kinase activity (Source: Nature Reviews Drug Discovery). Clinically, targeting the mTORC1 via the FKBP12–FRB interface is a validated strategy for immunosuppression in organ transplantation and for treating malignancies like renal cell carcinoma and tuberous sclerosis complex-related tumors (Source: NIH StatPearls). However, because mTORC1 is vital for normal physiology, its inhibition can lead to side effects such as metabolic dysregulation, stomatitis, and impaired wound healing (Source: PubMed PMC4439161). Understanding the structural basis of this ternary complex has also paved the way for the development of next-generation inhibitors that leverage the FKBP12 binding site for enhanced specificity (Source: Journal of Medicinal Chemistry).

Other names

mTORC1FKBP12-rapamycin-mTOR complexFKBP12-rapamycin-binding domain complexFRAP1RAFT1RAPT1

Allosteric inhibition of mTORC1 through the formation of a gain-of-function ternary complex where the drug acts as a molecular glue between FKBP12 and the FRB domain of mTOR.